Exicure Past Earnings Performance
Past criteria checks 0/6
Exicure has been growing earnings at an average annual rate of 10.1%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 22.7% per year.
Key information
10.1%
Earnings growth rate
26.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 22.7% |
| Return on equity | -604.3% |
| Net Margin | -2,667.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Exicure makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1 | -13 | 11 | 0 |
| 31 Dec 23 | 0 | -17 | 13 | 0 |
| 30 Sep 23 | 22 | 3 | 12 | 0 |
| 30 Jun 23 | 24 | 3 | 12 | 0 |
| 31 Mar 23 | 26 | 1 | 11 | 0 |
| 31 Dec 22 | 29 | -3 | 11 | 0 |
| 30 Sep 22 | 9 | -35 | 13 | 0 |
| 30 Jun 22 | 3 | -53 | 13 | 0 |
| 31 Mar 22 | 1 | -60 | 13 | 0 |
| 31 Dec 21 | 0 | -64 | 13 | 0 |
| 30 Sep 21 | -2 | -63 | 12 | 0 |
| 30 Jun 21 | 4 | -48 | 11 | 0 |
| 31 Mar 21 | 8 | -38 | 10 | 0 |
| 31 Dec 20 | 17 | -25 | 10 | 0 |
| 30 Sep 20 | 17 | -22 | 9 | 0 |
| 30 Jun 20 | 15 | -19 | 9 | 0 |
| 31 Mar 20 | 10 | -20 | 9 | 0 |
| 31 Dec 19 | 1 | -26 | 9 | 0 |
| 30 Sep 19 | 1 | -21 | 8 | 0 |
| 30 Jun 19 | 1 | -21 | 8 | 0 |
| 31 Mar 19 | 0 | -22 | 8 | 0 |
| 31 Dec 18 | 0 | -22 | 8 | 0 |
| 30 Sep 18 | 2 | -21 | 8 | 0 |
| 30 Jun 18 | 5 | -18 | 8 | 0 |
| 31 Mar 18 | 7 | -14 | 8 | 0 |
| 31 Dec 17 | 10 | -11 | 7 | 0 |
| 30 Sep 17 | 8 | -13 | 6 | 0 |
| 30 Jun 17 | 6 | -15 | 5 | 0 |
| 31 Mar 17 | 3 | -16 | 4 | 0 |
| 31 Dec 16 | 1 | -17 | 4 | 0 |
| 31 Dec 15 | 2 | -6 | 5 | 0 |
Quality Earnings: 2H0A is currently unprofitable.
Growing Profit Margin: 2H0A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2H0A is unprofitable, but has reduced losses over the past 5 years at a rate of 10.1% per year.
Accelerating Growth: Unable to compare 2H0A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2H0A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 2H0A has a negative Return on Equity (-604.26%), as it is currently unprofitable.